BDBM357048 US10214512, Example 28::methyl (9-(5-(3-chloro-2- fluoro-6-(1h-tetrazol-1- yl)phenyl)pyridin-2-yl)-4-oxo- 3-aza-1(1,3),2(1,2)- dibenzenacyclononaphane-24- yl)carbamate
SMILES: COC(=O)Nc1ccc-2c(NC(=O)CCCCC(c3cccc-2c3)c2ccc(cn2)-c2c(F)c(Cl)ccc2-n2cnnn2)c1
InChI Key: InChIKey=LWSVGTWSIPMVFX-UHFFFAOYSA-N
Data: 2 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Coagulation factor XI (Homo sapiens (Human)) | BDBM357048 (US10214512, Example 28 | methyl (9-(5-(3-chloro-2-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 0.240 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Sharp & Dohme Corp. US Patent | Assay Description The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine... | US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Kallikrein 1 (Homo sapiens (Human)) | BDBM357048 (US10214512, Example 28 | methyl (9-(5-(3-chloro-2-...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 1.57 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Sharp & Dohme Corp. US Patent | Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a... | US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN | |||||||||||
More data for this Ligand-Target Pair |